Safety and efficacy of micropulse transscleral cyclophotocoagulation: 2-year follow-up in a tertiary Canadian centre

Published:November 08, 2022DOI:



      To describe the long-term results of patients undergoing micropulse cyclophotocoagulation (MPCPC).


      Retrospective review of patients undergoing MPCPC with 1 surgeon between July 2016 and January 2017. Data collected included preoperative intraocular pressure (IOP), number of medications, daily acetazolamide use, and whether inferior, superior, or circumferential MPCPC was performed. This was assessed at postoperative week 1 and postoperative months 1, 3, 6, 12, 18, and 24.


      A total of 49 patients undergoing MPCPC with 2-year follow-up data was included. Ages ranged from 20 to 91 years (mean age, 69 years; 50% female). Following MPCPC, IOP was significantly lower at all points of follow-up (p < 0.05). At 2-year follow-up, the average IOP was 15 mm Hg (35% reduction). Six patients remained on acetazolamide (average daily dose, 333 mg). Average number of medications had decreased to 2.6 (p > 0.05). No significant structural complications occurred, but 53% required repeat MPCPC applications. The most common complication was failure requiring a secondary IOP-lowering surgical procedure. This occurred in 33% of patients. Subsequent glaucoma surgeries included gonioscopy-assisted transluminal trabeculotomy, iStent, Xen glaucoma implant, and Ahmed glaucoma valve.


      MPCPC was successful in reducing IOP in conjunction with a nonsignificant reduction in topical glaucoma medications. However, a large proportion of patients required repeat micropulse applications or invasive glaucoma surgery to achieve IOP control. These results suggest that the clinical efficacy of MPCPC may be lower than that reported in the literature.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Harasymowycz P
        • Birt C
        • Gooi P
        • et al.
        Medical management of glaucoma in the 21st century from a Canadian perspective.
        J Ophthalmol. 2016; 2016: 1-22
        • Flaxman SR
        • Bourne RRA
        • Resnikoff S
        • et al.
        Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis.
        Lancet Glob Heal. 2017; 5: e1221-e1234
        • Tham Y-C
        • Li X
        • Wong TY
        • Quigley HA
        • Aung T
        • Cheng C-Y.
        Global prevalence of glaucoma and projections of glaucoma burden through 2040.
        Ophthalmology. 2014; 121: 2081-2090
        • Quigley HA
        • Broman AT.
        The number of people with glaucoma worldwide in 2010 and 2020.
        Br J Ophthalmol. 2006; 90: 262-267
        • Hennis A
        • Wu S-Y
        • Nemesure B
        • et al.
        Awareness of incident open-angle glaucoma in a population study.
        Ophthalmology. 2007; 114: 1816-1821
        • Weinreb RN
        • Aung T
        • Medeiros FA.
        The pathophysiology and treatment of glaucoma.
        JAMA. 2014; 311: 1901
        • Friedman DS
        • Wolfs RCW
        • O'Colmain BJ
        • et al.
        Prevalence of open-angle glaucoma among adults in the United States.
        Arch Ophthalmol. 2004; 122: 532
        • Boland MV.
        • Ervin A-M
        • Friedman DS
        • et al.
        Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force.
        Ann Intern Med. 2013; 158: 271
        • Schlote T
        • Derse M
        • Rassmann K
        • Nicaeus T
        • Dietz K
        • Thiel HJ.
        Efficacy and safety of contact transscleral diode laser cyclophotocoagulation for advanced glaucoma.
        J Glaucoma. 2001; 10: 294-301
        • Oguri A
        • Takahashi E
        • Tomita G
        • Yamamoto T
        • Jikihara S
        • Kitazawa Y.
        Transscleral cyclophotocoagulation with the diode laser for neovascular glaucoma.
        Ophthalmic Surg Lasers. 1998; 29: 722-727
        • Mistlberger A
        • Liebmann JM
        • Tschiderer H
        • Ritch R
        • Ruckhofer J
        • Grabner G
        Diode laser transscleral cyclophotocoagulation for refractory glaucoma.
        J Glaucoma. 2001; 10: 288-293
        • Pantcheva MB
        • Kahook MY
        • Schuman JS
        • Rubin MW
        • Noecker RJ.
        Comparison of acute structural and histopathological changes of the porcine ciliary processes after endoscopic cyclophotocoagulation and transscleral cyclophotocoagulation.
        Clin Exp Ophthalmol. 2007; 35: 270-274
        • Berger JW.
        Thermal modelling of micropulsed diode laser retinal photocoagulation.
        Lasers Surg Med. 1997; 20: 409-415
        • Mastrobattista JM
        • Luntz M.
        Ciliary body ablation: where are we and how did we get here?.
        Surv Ophthalmol. 1996; 41: 193-213
        • Kosoko O
        • Gaasterland DE
        • Pollack IP
        • Enger CL.
        Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group.
        Ophthalmology. 1996; 103: 1294-1302
        • Ndulue JK
        • Rahmatnejad K
        • Sanvicente C
        • Wizov SS
        • Moster MR.
        Evolution of cyclophotocoagulation.
        J Ophthalmic Vis Res. 2018; 13: 55-61
        • Yadav NK
        • Jayadev C
        • Rajendran A
        • Nagpal M.
        Recent developments in retinal lasers and delivery systems.
        Indian J Ophthalmol. 2014; 62: 50-54
        • Friberg TR
        • Karatza EC.
        The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser.
        Ophthalmology. 1997; 104: 2030-2038
        • Kuchar S
        • Moster MR
        • Reamer CB
        • Waisbourd M.
        Treatment outcomes of micropulse transscleral cyclophotocoagulation in advanced glaucoma.
        Lasers Med Sci. 2016; 31: 393-396
        • Aquino MCD
        • Barton K
        • Tan AMW
        • et al.
        Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study.
        Clin Exp Ophthalmol. 2015; 43: 40-46
        • Tan AM
        • Chockalingam M
        • Aquino MC
        • Lim ZIL
        • See JLS
        • Chew PT.
        Micropulse transscleral diode laser cyclophotocoagulation in the treatment of refractory glaucoma.
        Clin Exp Ophthalmol. 2010; 38: 266-272
        • Emanuel ME
        • Grover DS
        • Fellman RL
        • et al.
        Micropulse cyclophotocoagulation: initial results in refractory glaucoma.
        J Glaucoma. 2017; 26: 726-729
        • Williams AL
        • Moster MR
        • Rahmatnejad K
        • et al.
        Clinical efficacy and safety profile of micropulse transscleral cyclophotocoagulation in refractory glaucoma.
        J Glaucoma. 2018; 27: 445-449